Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Guidance released for $1 billion in tax credits

This article was originally published in The Gray Sheet

Executive Summary

Beginning June 21, qualifying companies with 250 or fewer employees may apply for the new Therapeutic Discovery Project Program tax credit, assuming their projects "show a reasonable potential" to address unmet medical needs, reduce health care costs or advance cancer research. The application period runs through July 21, 2010. HHS will evaluate applications and the IRS will issue certifications no later than Oct. 29, 2010. Individual tax credits of up to $5 million are available per qualifying firm to cover up to 50% of the cost of qualifying biomedical research in 2009 and 2010. Firms can opt for a grant instead. The Treasury Department and National Institutes of Health jointly announced the 1guidelines on May 21. Authorization for the tax credit was included in the recent health reform law

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT028912

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel